Active CLL with Mutated IGHV, No TP53 Mutation: Treatment in Medically Unfit Patients with Significant Comorbidity
Chronic lymphocytic leukemia (CLL) presenting with mutated IGHV status and without TP53 mutation or del(17p) represents a distinct clinical subgroup. When the patient is medically unfit due to significant comorbidity, this shapes the treatment approach in important ways — as addressed by this structured protocol.
Active CLL with mutated IGHV status, confirmed absence of TP53 mutation and del(17p), in a patient who is not medically fit. Significant comorbidity is a central factor in this setting and directly informs the choice and sequencing of treatment options available to this patient.
For eligible patients in this clinical setting, stem cell transplantation and cellular therapy approaches within clinical trials are among the interventions addressed in the full protocol — with eligibility criteria and sequencing detailed within.
References
- CLL with mutated IGHV status and without TP53 mutation or del(17p) (if there was similar efficacy, panel is giving preference to time-limited therapies):
- Unfit patients: venetoclax plus obinutuzumab [I, A] or chlorambucil plus obinutuzumab or ibrutinib or acalabrutinib [I, A].
- Allogeneic stem cell transplantation (alloSCT) should be considered in:
- Patients refractory to CIT and to novel inhibitor therapy, even for patients with a higher risk of non-relapse mortality [haematopoietic cell transplant comorbidity index (HCT-CI) score of 3] [III, B];
- Treatment with chimeric antigen receptor T (CAR-T) cells or bi-specific T-cell engager (BiTE) antibodies within clinical trials could be an alternative to alloSCT for all three groups [V, B].